Ernexa Therapeutics stock soars 140% in a month as ERNA-101 shows complete tumor clearance and long-term survival in pre-clinical ovarian cancer models.
Ernexa Therapeutics Inc. (NASDAQ: ERNA - Get Free Report) saw a significant growth in short interest in the month of February. As of February 27th, there was short interest totaling 247,054 shares, a growth of 136.9% from the February 12th total of 104,299 shares. Currently, 3.3% of the company's shares are sold short. Based on an